Does Rallies show 13F holders for CGTX?

Yes. Rallies tracks hedge fund and 13F ownership data for CGTX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CGTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CGTX. It does not provide personalized investment advice.

CGTX (Cognition Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Cognition Therapeutics, Inc. Common Stock (CGTX) is a publicly traded Healthcare sector company. As of May 21, 2026, CGTX trades at $1.25 with a market cap of $97.55M and a P/E ratio of -3.98. CGTX moved +15.32% today. Year to date, CGTX is -7.86%; over the trailing twelve months it is +281.43%. Its 52-week range spans $0.22 to $3.83. Analyst consensus is buy with an average price target of $3.50. Rallies surfaces CGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CGTX stock?

Hedge funds tracked by Rallies that own CGTX include Renaissance Technologies and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cognition Therapeutics, Inc. Common Stock.

CGTX Key Metrics

Key financial metrics for CGTX
Metric	Value
Price	$1.25
Market Cap	$97.55M
P/E Ratio	-3.98
EPS	$-0.32
Dividend Yield	0.00%
52-Week High	$3.83
52-Week Low	$0.22
Volume	34.92K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-23.49M
Gross Margin	0.00%

Top Hedge Funds Holding CGTX

Renaissance Technologies holds 91.10K shares of CGTX, changed +2.71% as of Dec 31, 2024.
Two Sigma holds 53.69K shares of CGTX, changed +372.22% as of Dec 31, 2024.

Latest CGTX News

Cognition Therapeutics Secures FDA Path Forward for Zervimesine Registrational DLB Psychosis Study — May 21, 2026
Two Hantavirus Deaths Spotlight Therapy Gap, Elevating CGTX Antiviral Pipeline — May 12, 2026
Cognition Therapeutics Q1 Loss Narrows to $4.6M, FDA Meeting Set for DLB Psychosis — May 7, 2026
Cognition Therapeutics to Present CT1812 Data, Initiate Late-Stage DLB Psychosis Study on April 13 — Apr 7, 2026
Cognition Therapeutics Secures Cash Through Q2 2027, Advances Zervimesine DLB Trials — Mar 26, 2026

Recent CGTX Insider Trades

Doyle John Brendan bought 10.00K (~$11.30K) on Apr 16, 2026.
Ricciardi Lisa bought 9.18K (~$10.09K) on Apr 16, 2026.
Caggiano Anthony bought 10.00K (~$11.10K) on Apr 16, 2026.

CGTX Analyst Consensus

2 analysts cover CGTX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.50.

Common questions about CGTX

Who owns CGTX stock?: Hedge funds tracked by Rallies that own CGTX include Renaissance Technologies and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cognition Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for CGTX?: Yes. Rallies tracks hedge fund and 13F ownership data for CGTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CGTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CGTX. It does not provide personalized investment advice.